First Time Loading...

Chongkundang Holdings Corp
KRX:001630

Watchlist Manager
Chongkundang Holdings Corp Logo
Chongkundang Holdings Corp
KRX:001630
Watchlist
Price: 60 400 KRW -0.98% Market Closed
Updated: May 10, 2024
Section:
 

Relative Value

The Relative Value of one Chongkundang Holdings Corp stock under the Base Case scenario is 133 116.66 KRW. Compared to the current market price of 60 400 KRW, Chongkundang Holdings Corp is Undervalued by 55%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
133 116.66 KRW
Undervaluation 55%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

0.3
P/S
P/S
Price to Sales
0.3
vs History
66
vs Industry
88
Median 3Y
0.3
Median 5Y
0.4
Industry
2.5
Forward
0.3
More Details
6.1
P/E
P/E
Price to Earnings
6.1
vs History
90
vs Industry
41
Median 3Y
8.6
Median 5Y
10.6
Industry
23.4
Forward
38.3
More Details
7.7
P/OCF
P/OCF
Price to OCF
7.7
vs History
36
vs Industry
40
Median 3Y
7.6
Median 5Y
6.6
Industry
17.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-6.6
Median 5Y
8.1
Industry
23.6
More Details
0.5
P/B
P/B
Price to Book Value
0.5
vs History
69
vs Industry
74
Median 3Y
0.5
Median 5Y
0.7
Industry
2.1
More Details
0.6
EV/S
EV/S
Enterprise Value to Sales
0.6
vs History
73
vs Industry
81
Median 3Y
0.6
Median 5Y
0.7
Industry
2.6
Forward
0.6
More Details
1.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
1.4
vs History
68
vs Industry
78
Median 3Y
1.4
Median 5Y
1.5
Industry
5.2
More Details
8.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
8.7
vs History
38
vs Industry
38
Median 3Y
11.2
Median 5Y
7.4
Industry
13.7
Forward
8.6
More Details
30.9
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
30.9
vs History
14
vs Industry
14
Median 3Y
10.9
Median 5Y
6.7
Industry
17.2
Forward
76.3
More Details
14.5
EV/OCF
EV/OCF
Enterprise Value to OCF
14.5
vs History
17
vs Industry
30
Median 3Y
11.7
Median 5Y
8.4
Industry
16.2
More Details
106.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
106.4
vs History
4
vs Industry
5
Median 3Y
-7.6
Median 5Y
-10.2
Industry
17.8
More Details
0.4
EV/IC
EV/IC
Enterprise Value to IC
0.4
vs History
93
vs Industry
77
Median 3Y
0.5
Median 5Y
0.5
Industry
2
More Details

Multiples Across Competitors

Competitors Multiples
Chongkundang Holdings Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
Chongkundang Holdings Corp
KRX:001630
287.5B KRW 0.3 6.1 8.7 30.9
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
729.1B USD 20.3 118.5 58.2 66.2
DK
Novo Nordisk A/S
CSE:NOVO B
3.9T DKK 16.1 44.1 32.9 36.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
359.9B USD 4.2 9.4 11.5 15
US
Merck & Co Inc
NYSE:MRK
330.2B USD 5.4 143.2 35.7 58.2
UK
AstraZeneca PLC
LSE:AZN
191.8B GBP 5 37.9 174.6 278.6
CH
Roche Holding AG
SIX:ROG
180.2B CHF 3.1 15.7 8.9 10.6
CH
Novartis AG
SIX:NOVN
180.3B CHF 3.4 11.4 8.6 12.6
US
Pfizer Inc
NYSE:PFE
158.4B USD 2.9 -512.4 12.7 20.3
P/E Multiple
Earnings Growth
KR
Chongkundang Holdings Corp
KRX:001630
Average P/E: 48.3
6.1
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
118.5
346%
DK
Novo Nordisk A/S
CSE:NOVO B
44.1
84%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9.4
-20%
US
Merck & Co Inc
NYSE:MRK
143.2
7 454%
UK
AstraZeneca PLC
LSE:AZN
37.9
168%
CH
Roche Holding AG
SIX:ROG
15.7
26%
CH
Novartis AG
SIX:NOVN
11.4
15%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -512.4
680%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 136,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.